Company Overview - Exelixis shares have decreased by approximately 7.2% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Exelixis have trended upward in the past month, with the consensus estimate shifting by 15.91% [2] VGM Scores - Exelixis has a strong Growth Score of A and a momentum score of A, with a value score of B, placing it in the top 40% for this investment strategy [3] - The aggregate VGM Score for Exelixis is A, indicating strong overall performance across multiple investment strategies [3] Outlook - The upward trend in estimates suggests a promising outlook for Exelixis, which holds a Zacks Rank 2 (Buy) [4] - An above-average return is expected from the stock in the upcoming months [4] Industry Performance - Exelixis is part of the Zacks Medical - Biomedical and Genetics industry, where Puma Biotech has gained 22.1% over the past month [5] - Puma Biotech reported revenues of $46 million for the last quarter, reflecting a year-over-year increase of 5% [5] - Puma Biotech's expected earnings for the current quarter are $0.11 per share, indicating a significant change of 320% from the previous year [6] - Puma Biotech also holds a Zacks Rank 2 (Buy) and has a VGM Score of A [6]

Group 1 - United Natural Foods (UNFI) reported quarterly earnings of $0.44 per share, exceeding the Zacks Consensus Estimate of $0.24 per share, and showing a significant increase from $0.10 per share a year ago, representing an earnings surprise of 83.33% [1] - The company achieved revenues of $8.06 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.71% and increasing from $7.5 billion year-over-year [2] - United Natural has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Group 2 - The stock has underperformed the market, losing about 5% since the beginning of the year, while the S&P 500 has gained 2.1% [3] - The company's earnings outlook is mixed, with current consensus EPS estimates at $0.19 for the coming quarter and $0.82 for the current fiscal year, with revenues expected to be $7.7 billion and $31.58 billion respectively [7] - The Zacks Industry Rank for Food - Miscellaneous is currently in the bottom 33% of over 250 Zacks industries, which may impact the stock's performance [8]

Financial Performance - MongoDB reported quarterly earnings of $1 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, and up from $0.51 per share a year ago, representing an earnings surprise of 53.85% [1] - The company posted revenues of $549.01 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 4.23%, and an increase from $450.56 million year-over-year [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $546.56 million, and for the current fiscal year, it is $2.56 on revenues of $2.26 billion [7] - The estimate revisions trend for MongoDB is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Internet - Software industry, to which MongoDB belongs, is currently in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Overview - Recursion Pharmaceuticals (RXRX) shares have increased by approximately 5.7% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the stock's performance and potential catalysts [1] Earnings Estimates - Estimates for Recursion Pharmaceuticals have trended upward in the past month, with a consensus estimate shift of 10.13% [2] VGM Scores - The company has a poor Growth Score of F, a Momentum Score of A, and a Value Score of F, placing it in the bottom 20% for the value investment strategy [3] - The aggregate VGM Score for Recursion Pharmaceuticals is F, indicating a lack of focus on any single investment strategy [3] Outlook - The upward trend in estimates is promising, and Recursion Pharmaceuticals holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Industry Comparison - Recursion Pharmaceuticals is part of the Zacks Medical - Drugs industry, where Ionis Pharmaceuticals (IONS) has gained 9.1% over the past month [5] - Ionis Pharmaceuticals reported revenues of $132 million for the last quarter, reflecting a year-over-year increase of 10.9% [5] - For the current quarter, Ionis Pharmaceuticals is expected to report a loss of $0.14 per share, indicating a 68.9% improvement from the previous year [6]

Core Viewpoint - Guidewire Software reported strong quarterly earnings of $0.88 per share, significantly exceeding the Zacks Consensus Estimate of $0.46 per share, and showing a substantial increase from $0.26 per share a year ago [1][2]. Financial Performance - The company achieved revenues of $293.51 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.73% and up from $240.68 million year-over-year [3]. - Guidewire Software has consistently outperformed consensus estimates, surpassing EPS estimates three out of the last four quarters and revenue estimates four times in the same period [2][3]. Stock Performance - Since the beginning of the year, Guidewire Software shares have increased by approximately 27.7%, in contrast to the S&P 500's gain of 0.9% [4]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.59, with projected revenues of $331.29 million, while the estimate for the current fiscal year is $1.97 on revenues of $1.17 billion [8]. - The outlook for the Internet - Software industry is favorable, ranking in the top 22% of over 250 Zacks industries, suggesting potential for outperformance [9].

Core Viewpoint - Red Robin (RRGB) reported quarterly earnings of $0.19 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.57 per share, and showing improvement from a loss of $0.80 per share a year ago [1] Financial Performance - The company posted revenues of $392.35 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.28% and showing an increase from $388.54 million year-over-year [2] - Over the last four quarters, Red Robin has exceeded consensus revenue estimates four times, but has only surpassed consensus EPS estimates once [2] Stock Performance - Red Robin shares have declined approximately 39.2% since the beginning of the year, contrasting with the S&P 500's slight gain of 0.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $291.24 million, and for the current fiscal year, it is -$1.88 on revenues of $1.23 billion [7] - The estimate revisions trend for Red Robin is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - The Retail - Restaurants industry, to which Red Robin belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Comparatively, Darden Restaurants (DRI), another player in the same industry, is expected to report quarterly earnings of $2.92 per share, reflecting a year-over-year increase of 10.2% [9]

Group 1: Roivant Sciences Ltd. Performance - Roivant Sciences Ltd. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.16, representing an earnings surprise of -37.50% [1] - The loss per share has improved slightly from a loss of $0.23 per share a year ago [1] - In the previous quarter, the company had a loss of $0.13 per share against an expected loss of $0.24, resulting in a positive surprise of 45.83% [1] Group 2: Montes Archimedes Acquisition Performance - Montes Archimedes Acquisition reported revenues of $7.57 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 88.76%, and down from $28.93 million year-over-year [2] - The company has surpassed consensus revenue estimates two times over the last four quarters [2] - The stock has underperformed, losing about 10.2% since the beginning of the year compared to the S&P 500's gain of 0.1% [3] Group 3: Earnings Outlook and Estimates - The current consensus EPS estimate for Montes Archimedes Acquisition is -$0.25 on revenues of $3.89 million for the coming quarter, and -$1.01 on revenues of $28.53 million for the current fiscal year [7] - The estimate revisions trend for the company is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is currently in the top 30% of Zacks industries, which historically outperforms the bottom 50% by a factor of more than 2 to 1 [8] Group 4: Industry Context - Beyond Air, Inc., another company in the same industry, is expected to report a quarterly loss of $0.14 per share, reflecting a year-over-year change of +61.1%, with revenues expected to be $1.39 million, up 195.7% from the year-ago quarter [9]

分组1 - Agilent Technologies reported quarterly earnings of $1.31 per share, exceeding the Zacks Consensus Estimate of $1.26 per share, and showing an increase from $1.22 per share a year ago, representing an earnings surprise of 3.97% [1] - The company achieved revenues of $1.67 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.64% and increasing from $1.57 billion year-over-year [2] - Agilent has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - Despite the positive earnings report, Agilent shares have declined approximately 17.2% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $1.40 on revenues of $1.65 billion, and for the current fiscal year, it is $5.54 on revenues of $6.73 billion [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Products industry is currently in the bottom 44% of over 250 Zacks industries, which may negatively impact Agilent's stock performance [8] - The estimate revisions trend for Agilent is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

Group 1: Earnings Performance - Box reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of $0.25 per share, but down from $0.39 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of $276.27 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.67% and up from $264.66 million year-over-year [2] - Over the last four quarters, Box has consistently surpassed consensus EPS and revenue estimates [2] Group 2: Stock Performance and Outlook - Box shares have declined approximately 1.6% since the beginning of the year, compared to a decline of 1.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.28 on revenues of $283.88 million, and for the current fiscal year, it is $1.19 on revenues of $1.15 billion [7] - The estimate revisions trend for Box is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Group 3: Industry Context - The Internet - Software industry, to which Box belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Box's stock performance [5]

Core Viewpoint - Silvercorp reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share, but showing an improvement from $0.02 per share a year ago, indicating a -22.22% earnings surprise [1] Financial Performance - The company posted revenues of $75.11 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.02%, and showing significant growth from year-ago revenues of $42.68 million [2] - Over the last four quarters, Silvercorp has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - Silvercorp shares have increased approximately 30.3% since the beginning of the year, contrasting with the S&P 500's decline of -0.6% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.10 for the coming quarter and $0.30 for the current fiscal year, alongside expected revenues of $85 million and $287.7 million respectively [7] - The estimate revisions trend for Silvercorp is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the shares are expected to perform in line with the market in the near future [6] Industry Context - The Mining - Miscellaneous industry, to which Silvercorp belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating that the industry's outlook can significantly impact the stock's performance [8]